



Sensei Biotherapeutics Announces Appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer

GAITHERSBURG, MD and BOSTON, MA – June 15, 2020 – Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer, responsible for leading clinical and development strategy and operations. Dr. Fjällskog joins Sensei from Merus, where she served as Vice President Clinical Development and led the development of several clinical and preclinical bispecific antibody therapeutics.

“We are thrilled to welcome Marie-Louise to our team. Her deep knowledge of oncology research and medicine from both an industry and academic perspective are a strong addition to Sensei as we prepare for key Phase 2 readouts and additional INDs in the coming months,” said John Celebi, CEO of Sensei Biotherapeutics. “I’m excited to welcome her to Sensei as she shares our commitment to patients, our values, and culture. Her experience developing early stage programs into commercial products will be instrumental as our pipeline continues to mature and we evolve into a late-stage oncology development company over the next several years.”

“Sensei’s unique approach represents an exciting new wave of oncology research and development that I am extremely excited to be a part of,” said Marie-Louise Fjällskog, M.D., Ph.D., Chief Medical Officer of Sensei Biotherapeutics. “I look forward to continuing the development of SNS-301 and working to expand the company’s pipeline. Immunophage therapies are a new approach for cancer and infectious diseases that have the potential to drive precise antigen specific immunity and stimulate key immunomodulatory signals.”

Before assuming her most recent role at Merus, Dr. Fjällskog served as Vice President of Clinical Development at Infinity Pharmaceuticals, where she played an integral role in the expanded clinical development of IPI-549. Earlier, she worked at the Novartis Institute for Biomedical Research, where she served as a Clinical Program Leader, Translational Clinical Oncology and as the global lead for several oncology programs, including those targeting CDK4/6, BCL-2, CSF-1, PD-1 and CD73. Dr. Fjällskog is an Associate Professor of Oncology at Uppsala University, Sweden and has over twenty-five years of experience in clinical oncology, translational research, and drug development. She holds an M.D. and Ph.D. from Uppsala University School of Medicine.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of precision immuno-oncology therapies to transform the cancer treatment landscape. The company has developed a unique phage-based platform, *ImmunoPhage*[™], that enables the generation of immune activating agents that fully engage the immune system. Its most advanced program, SNS-301, is currently enrolling patients in Phase 2 clinical trials. The company brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. For more information, please visit www.senseibio.com.

Media Contact:

Kathryn Morris
The Yates Network



914-204-6412

kathryn@theyatesnetwork.com

Investor Contact:

Julie Seidel

Stern Investor Relations, Inc.

212-362-1200

julie.seidel@sternir.com